CTOR — Citius Oncology Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Citius Oncology, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -5.43 | -12.7 | -21.1 | -24.8 |
| Deferred Taxes | ||||
| Non-Cash Items | 0 | 1.97 | 7.5 | 8.32 |
| Other Non-Cash Items | ||||
| Changes in Working Capital | 4.86 | 10.2 | 13.2 | 9.89 |
| Change in Inventories | ||||
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Cash from Operating Activities | 0 | 0 | 0.126 | -5.49 |
| Other Investing Cash Flow Items | 0 | 0 | -5 | -5.75 |
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | 0 | 0 | -5 | -5.75 |
| Financing Cash Flow Items | 0 | 0 | 1.07 | — |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 0 | 0 | 4.87 | 15.2 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0 | 0 | 0 | 3.92 |